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ABSTRACT: Determination of progesterone receptor (PR) status in hormone-depend-
ent diseases is essential in ascertaining disease prognosis and monitoring treatment
response. The development of a noninvasive means of monitoring these processes would
have significant impact on early detection, cost, repeated measurements, and personalized
treatment options. Magnetic resonance imaging (MRI) is widely recognized as a technique
that can produce longitudinal studies, and PR-targeted MR probes may address a clinical
problem by providing contrast enhancement that reports on PR status without biopsy.
Commercially available MR contrast agents are typically delivered via intravenous
injection, whereas steroids are administered subcutaneously. Whether the route of delivery
is important for tissue accumulation of steroid-modified MRI contrast agents to PR-rich
tissues is not known. To address this question, modification of the chemistry linking
progesterone with the gadolinium chelate led to MR probes with increased water solubility
and lower cellular toxicity and enabled administration through the blood. This attribute
came at a cost through lower affinity for PR and decreased ability to cross the cell membrane, and ultimately it did not improve
delivery of the PR-targeted MR probe to PR-rich tissues or tumors in vivo. Overall, these studies are important, as they
demonstrate that targeted contrast agents require optimization of delivery and receptor binding of the steroid and the gadolinium
chelate for optimal translation in vivo.
■ INTRODUCTION
Small molecule imaging probes have been extensively studied
to monitor and quantify physiological processes.1,2 Steroid
receptors are an example of a target for this type of probe
because these proteins regulate a number of cell processes
through transcriptional regulation of genes.3 The ability to
noninvasively interrogate the function of these important
receptors will guide the development of new therapeutic targets
for hormone-dependent diseases such as endometriosis and
breast, ovarian, uterine, and prostate cancers.4−6 Some
commonly prescribed chemotherapeutics, such as the estrogen
receptor (ER)-targeting tamoxifen, are designed to block the
steroid receptor activity that facilitates tumor growth, and
receptor status is frequently determined for these diseases prior
to treatment.7,8 The presence of both receptors, PR and ER, in
breast cancer correlates positively with patient survival rate,
whereas the loss of steroid receptor expression coincides with
the disease becoming more aggressive and drug resistant.9−11
Furthermore, triple-negative breast cancer, tumors that do not
express PR, ER, or a third important marker, Her2, stands as
the most aggressive subtype. Treatment of receptor-negative
disease requires a wholly different approach when compared to
that for receptor-expressing cells. Noninvasively determining
receptor status may be critical in detecting new lesions,
categorizing tumors, and determining when disease is becoming
refractory with current treatment, thus improving disease
prognosis. Due to this significant role of steroid receptors in
tumor progression, these proteins represent excellent imaging
targets for noninvasive molecular characterization and monitor-
ing of cancers and benign disease states such as endome-
triosis.12,13
In vivo imaging of steroid receptors has been demonstrated
using positron emission tomography (PET).12,14−18 However,
rapid metabolism of probes by 20-hydroxysteroid dehydrogen-
ase limited the use of these probes in human subjects.19−21 In
addition, PET can be restricted by limited spatial and temporal
resolution.2,19,22 In contrast, MRI has high temporal and spatial
resolution without exposing patients to radiation.2 Typically,
MRI uses contrast agents to increase local signal intensity by
distinguishing tissues or organs that are magnetically similar but
histologically distinct. These probes make use of a para-
magnetic ion, Gd(III), that decreases the proton spin-lattice
relaxation time (T1) of protons.
23,24 This decrease in T1 is
manifested as bright regions in an acquired T1-weighted MR
image. Structural modification of the chelate provides the
opportunity to target specific pathological processes.23,25−31
Imaging probes targeted for ER and PR have many
similarities in their structure and function. The specificity for
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a given receptor lies in the targeting ligand that is used for
synthesis. A number of steroid receptor-targeted MRI contrast
agents have been developed.32−36 For example, ProGlo is a
progesterone receptor (PR)-targeted agent that has shown
promising cellular retention and selectivity in tissues and
tumors with elevated PR expression.32 The use of steroid
receptor-targeted MRI contrast agents has been limited to
preclinical research. Challenges with previous generations of
PR-targeted probes demonstrated the potential need for
modification due to the inability to test them using intravenous
(i.v.) injection, the most commonly employed method of
administration for clinically used MR contrast probes.34
To determine the relationship among complex linker length
and solubility, toxicity, tissue distribution, and MR contrast, we
synthesized and biologically evaluated a series of PR-targeted
MR imaging probes with variable linker length (Figure 1). By
systematic alteration of the aliphatic linker between the Gd(III)
chelate and the steroid, an increase in linker length could be
correlated to an increase in hydrophobicity. The most
hydrophilic complex exhibited the lowest toxicity in PR(+)
human breast cancer cells. In vivo, complex 1 preferentially
accumulated in tissues that expressed PR when injected either
i.v. or intraperitoneally (i.p.). The highest concentration of 1
was observed in the uterus after i.p. injection, indicating that i.v.
administration does not enhance PR-targeted MR probe
delivery. Complex 1 was additionally found to enhance PR-
rich tissues compared with muscle in T1-weighted images taken
at 9.4 T. Overall, further optimization through rational probe
design yielded PR-targeted contrast probes with increased
water solubility and allowed for multiple routes of in vivo
administration but ultimately did not appreciably alter delivery
to target tissues or provide a significant advancement in
contrast efficiency. These studies illustrate that optimization of
a targeted MR agent should include consideration of solubility
to change the route of delivery as well as steroid biology, which
dictates tissue accumulation.
■ RESULTS
Synthesis of a Series of PR-Targeted MRI Contrast
Agents with Varying Linker Lengths. Previous experiments
have demonstrated that ProGlo successfully targets PR
receptors in vivo while enhancing contrast in MR images of
tumor xenografts.32,34 The hydrophobicity of ProGlo and
solubility in aqueous media limited the method of in vivo
administration.34,35 Here, we have focused on preserving the
structural foundation of earlier generations of these probes
while increasing solubility to determine if delivery through the
blood enhances bioactivity (Figure 1).
Synthesis of complexes 1 and 4 were performed with minor
modification to published procedures.32 The synthesis of 2 and
3 was initiated with the coupling of either 1,4-dibromobutane
or 1,5-dibromopentane to 21-hydroxyprogesterone. In order
not to inhibit the binding affinity of the steroid, attachment of
the contrast probe was carried out on the D-ring (Figure
S1).37−39
Relaxivity and Octanol−Water Partition Coefficients.
The relaxivity of a MR contrast agent is defined by its ability to
increase the relaxation rates of the surrounding water proton
spins. The relaxivity values measured by the PR probes
described were similar to clinically used Gd(III) contrast agents
(Table 1). Octanol−water partition coefficients (logP values)
were measured and reflect the hydrophobicity of the agents
(Table 1). Compound 1 exhibited the most negative logP value
(−1.06 ± 0.02).33,40 Not surprisingly, complex 4, which has a
six carbon atom linker arm, was the most hydrophobic (logP
value of 1.40 ± 0.08). Complexes 2 (four carbon linker) and 3
(five carbon linker) have intermediate logP values around 0,
−0.08 ± 0.06 and 0.11 ± 0.01, respectively.
This trend in hydrophobicity is additionally mirrored in the
HPLC retention times of each complex. An evaporative light
scattering detector, ELSD, was used to obtain a trace of each
complex upon elution from a C18 column. The mobile phase
was a gradient ramp from 100% water to 100% acetonitrile.
Complex 1 was detected at 9.9 min and was the most
Figure 1. Structures of PR-targeted contrast probes, 1−4. The alkane
linker between the PR-targeting moiety and Gd(III) chelate was
modified to elucidate the effect of linker length on toxicity, receptor
binding, and tissue distribution in vivo.
Table 1. Characterization of PR-Targeted Contrast Agents
agent r1
a r2
a logP toxicity LC50
b competitive PR binding IC50
c
1 5.2 ± 0.3 5.7 ± 0.3 −1.06 ± 0.02 2.65 122 ± 26
2 6.9 ± 0.1 7.9 ± 0.1 −0.08 ± 0.06 1.23 0.80 ± 0.06
3 6.7 ± 0.3 7.6 ± 0.3 0.11 ± 0.01 1.00 1.80 ± 0.44
4 6.4 ± 0.1 7.4 ± 0.1 1.40 ± 0.08 0.88 0.95 ± 0.34
P4 N.D. N.D. 2.88d 0.002241 0.001632
ar1 and r2 measured in mM
−1 s−1 at 1.41 T, 37°. bLC50 measured in mM and determined by sinusoidal curve fitting of a dose response curve in
GraphPad Prism in T47D PR(+) cells. cIC50 measure in μM and determined by the equation mP100% + (mP0% − mP100%)/(1 + 10 log (IC50 −
X)), where Y = mP, X = Log [compound], mP100% = 100% inhibition, and mP0% = 0% inhibition. dMeasured by shake flask method/mass.42
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hydrophilic of the complexes. The addition of the aliphatic
linker caused a significant increase in retention time, as
corroborated in the logP values. Complexes 2 and 3 have
similar retention times at 16.1 and 16.7 min, respectively. The
most hydrophobic complex, 4, was retained longest on the
column, with an elution time of 17.3 min.
As previously observed, the Gd(III) chelate has a
pronounced effect on the binding affinity of progesterone to
the receptor as compared to unmodified progesterone.32,34 A
competitive binding assay quantified the effect of linker length
on the affinity of the contrast agents for PR (Figure 2), and
IC50 values are reported in Table 1. Complex 4 binds to PR
with a similar affinity as that previously observed.32 Complex 2
and 3 bound PR with a similar affinity to that of 4. Complex 1
demonstrated the lowest affinity for the receptor among the
series (p < 0.01), with almost 100-fold lower affinity compared
to that of 2−4.
Correlation Observed between LogP Values and
Cytotoxicity. One aspect of enhanced water solubility for
PR contrast agents may be that it reduces toxicity. MTS cell
viability assays determine the cytotoxicity of the probes in vitro
after incubation with varying concentrations of each complex in
PR(+) T47D or PR(−) MDA-MB-231 cells (Figure 3).
Cytotoxicity correlated to logP values in PR(+) T47D cells.
Complex 1 exhibited the lowest toxicity at all of the
concentrations tested and was the least hydrophobic.
Complexes 2−4 exhibited similar toxicity in a trend following
their logP values (reported in Table 1). In MDA-MB-231, all
agents had similar toxicity profiles, implying that probe toxicity
is associated with the presence of PR (Figure S2).
Correlation Observed between LogP Values and
Cellular Association. PR is an intracellular protein, and
interaction between the contrast probes and PR requires
cellular uptake utilizing a diffusion mechanism through the
cellular membrane. Uptake experiments of the probes to PR(+)
T47D and PR(−) MDA-MB-231 human breast cancer cells
evaluated the cell permeability of the probes. Time-dependent
uptake was not observed in the PR(−) cells for any of the
reported complexes where Gd(III) concentrations remained
consistent over all of the time points as measured by ICP-MS.
Time-dependent accumulation was observed for 1 and 2 in
PR(+) cells (Figure 4). Uptake of 3 and 4 in PR(+) cells
increased dramatically after 1 h, with higher accumulation at 4 h
before decreasing by 8 h. This trend in cellular accumulation
correlated to hydrophobicity, where the most hydrophobic
complex, 4, had the highest concentrations of probe in cells. In
PR(+) cells, the concentrations of all of the steroid-conjugated
probes are markedly higher than that found in PR(−) cells at all
time points. This suggests that PR plays a role in the retention
of these probes and that the ability to cross the cell membrane
correlated with hydrophobicity.
PR Activation Is Retained as Water Solubility
Increases. To further demonstrate that the MR probes cross
the cell membrane and bind PR, the ligand-activated tran-
scription factor activity of PR was exploited using a luciferase
reporter assay (Figure 5A). Upon activation, progesterone
receptors dimerize and bind to a region of DNA referred to as
the progesterone response element (PRE). Ligation of this
DNA element to a segment of DNA encoding the luciferase
gene can verify the activation of PR by these complexes through
the formation of a functional transcription complex. It was
expected that these agents have similar profiles of receptor
activation as that of the previously developed PR-targeted MR
complexes, as the chemical modification was performed in the
same position.
From the series of contrast agents, 4 activated transcription
of the luciferase reporter gene most effectively (29.6-fold
greater than solvent at 0.5 μM), whereas at the same
concentration, 3 and 2 activated the reporter gene to a lesser
extent (8.9- and 10.5-fold, respectively). Contrast agent 1
demonstrated the least transcriptional activation (1.2-fold). The
Figure 2. Relative binding affinity of complexes 1−4, compared with
an unmodified progesterone control (P4), to progesterone receptor.
As the linker length increases, the binding affinity of the probe is
improved. Error bars indicate ±SEM.
Figure 3. Cytotoxicity of complexes 1−4 as obtained through MTS
assay on the PR(+) T47D cell line. Complex 1 is the least toxic,
followed by 2, 3, and 4. Error bars indicate ±SEM.
Figure 4. Complexes accumulate preferentially in cells that express PR.
Time-dependent uptake experiments were performed in PR(−) MDA-
MB-231 cells (A) and PR(+) T47D cells (B). Error bars indicate
±SEM. Statistical difference determined using two-way ANOVA test.
* p < 0.05.
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most hydrophobic of compounds, 4 (ProGlo), was the most
effective transcriptional activator, which is expected, as this
complex displayed the highest binding affinity to PR. Due to
the hydrophilicity and low toxicity of 1, higher concentrations
of agent can be administered without harmful outcomes. The
luciferase assay demonstrated that at this higher concentration
of complex 1 a measurable higher activation of receptor
(comparable to complexes 2 and 3) was observed. Activation of
luciferase activity by progesterone and contrast agents is
effectively blocked with the progesterone antagonist RU486,
demonstrating that the activation of PR by these complexes is
specific (Figure S3).
Transcriptional activation of an endogenous PR-regulated
gene, ZBTB16, confirmed probe activation efficiency (Figure
5B). Similar to the luciferase reporter assay, 4 induced
transcription of ZBTB16 at the highest rate, followed by 3, 2,
and finally 1 being the least efficient while still maintaining the
ability to activate transcription. The highly lipophilic 4 appears
have the greatest ability to traverse the cell membrane and
activate transcription.
Accumulation of Complex 1 in Uterus after in Vivo i.p.
Injection. By evaluating the in vivo distribution of PR-targeted
complexes, we were able to distinguish if i.v. or i.p. injections
would be advantageous in terms of accumulation in PR-
expressing tissues. Despite lower cellular retention and PR
binding affinity, complex 1 was the only agent that was
completely soluble in saline. Therefore, 1 was the only agent
suitable for i.v. administration and was used to directly compare
if i.v. or i.p. administration could influence cellular accumu-
lation in PR-expressing organs. Given that most traditional MR
contrast agents are administered i.v., yet most steroids are
delivered i.p. or subcutaneously, a direct comparison of how the
steroid modified agent would accumulate in PR-expressing
tissues following standard i.p. and i.v. administration was
performed. Following i.v. or i.p. injection, the organs from
female CD-1 mice were harvested at 6 and 24 h. The total
nanograms of Gd(III) per gram of tissue, as measured by ICP-
MS, is shown in Figure 6.
On the basis of the expression of PR, the organs of interest
include the mammary gland, the ovaries, and the uterus. A
section of muscle was used as a negative control, as the probe
complexes should not accumulate in the muscle. The data is
presented normalized to the average saline ICP values. The
highest concentrations of Gd(III) from both routes of
administration were found in the uterus and ovaries, similar
to previous studies using MR and PET agents.12,34 The highest
concentration of complex 1 was found in the uterus from the
i.p. injection, significantly greater than corresponding accumu-
lation due to i.v. administration (Figure 6 and Figure S4). In
the ovary and mammary gland, 1 accumulated equivalently at 6
h but was greater after i.p. injection at 24 h. Taken together,
these results demonstrate that i.v. injection does not increase
delivery to PR-expressing tissues, suggesting i.v. administration
is not necessary for PR-targeted MR probes.
Complex 1 Enhanced PR(+) Tissues in Vivo. To
determine whether complex 1, dissolved in saline, would
increase the contrast-to-noise ratio of PR(+) relative to PR(−)
tumors in vivo, a preliminary xenograft tumor model in athymic
nude mice was utilized. T47D (PR(+)) cells on the left and
MDA-MB-231 (PR(−)) cells on the right were injected
subcutaneously. Mice (n = 2) were injected i.p. with 1 and
imaged at 6 h postinjection.
Contrast enhancement is observed above background muscle
in the PR(+) tumor, Figure 7A. To ensure that the change in
image contrast was due to the accumulation of Gd(III), the
tumors were harvested, and Gd(III) concentration was
quantified by ICP-MS, Figure 7B. The action of 1 did not
surpass that of previously synthesized complex 4 which more
effectively increased contrast resulting in a higher fold change
between MR signal preinjection and at each time point.34
■ DISCUSSION AND CONCLUSIONS
The presence and localization of steroid receptors (such as PR)
are important diagnostic and prognostic markers in hormone-
dependent diseases.40 The development of a noninvasive
Figure 5. Complexes retain the ability to activate PR after chemical
modification: the addition of the Gd(III) chelate to the PR-targeting
moiety. Incubation with complexes resulted in transcriptional
activation of the luciferase reporter gene (A). Transcription of an
endogenous PR-inducible gene was monitored (B). Complex 4 was
the most potent in both assays. Error bars indicate ±SEM. Statistical
differences as indicated by asterisks measured by one-way ANOVA
test. ** p < 0.05, * p < 0.05 (when compared to samples treated with
only DMSO).
Figure 6. Complex 1 accumulates in tissues that have high
concentrations of PR such as the uterus and ovary. 1 was injected
either i.v. or i.p. into CD-1 female mice, and organs were harvested
after 6 (A) or 24 (B) h. Data is presented normalized to saline ICP
values. Error bars indicate ±SEM. Statistical differences determined
through two-way ANOVA test. *** p < 0.0001, ** p < 0.001, * p <
0.05.
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method to probe PR status would allow for repeat measure-
ments, decreased patient discomfort, personalized treatment
decisions, and improved characterization of the tumor mass.
The previously developed PR-targeted MR probe, ProGlo,
exhibited selective accumulation and MR enhancement of PR-
rich tissues and tumors in vivo when delivered either i.p. or
s.c.34 The insolubility of ProGlo and other PR-targeted contrast
agents in aqueous solutions precluded the ability to investigate
i.v. administration. Synthesis of a linker length series of PR-
targeted MR probes was conducted to increase water solubility
and lower toxicity and to determine if administration route is
important for delivery. Of the three new MR probes, only
complex 1 was completely water soluble, enabling the direct
comparison between i.p. or i.v. injection for accumulation in
PR-expressing tissues.
With increasing water solubility of PR-targeted probes, a
mixture of positive and negative biological properties arose. As
hydrophilicity increased, the cytotoxicity of the complexes
decreased. Complex 4, ProGlo, was shown to be the most
hydrophobic and exhibited the highest toxicity, whereas the
water-soluble complex 1 demonstrated the lowest toxicity. The
increased toxicity of ProGlo can be partially attributed to
additional nonspecific interactions due to hydrophobicity;
conversely, it can also be attributed to progesterone signaling,
as progesterone itself can be toxic.35,41 However, with
increasing water solubility, other biological properties such as
receptor binding and the ability to cross the cell membrane
were blunted. The more hydrophilic the compound, the more
the likelihood that the probe will effectively be taken up into
cells decreases, as observed with the cell accumulation assay. In
addition, the binding of 1 to PR was decreased 100-fold
compared to that of 2−4, potentially due to increased steric
hindrance of the Gd(III) chelate. The decreased ability to cross
the cell membrane and bind PR was reflected in the lower
transcriptional activation. Taken together, an ideal amount of
each characteristic, hydrophobicity to allow for cell uptake and
hydrophilicity to increase probe safety, is essential for the
optimized PR-targeted contrast probe.
The optimal delivery route for a PR-targeted MR probe is
not straightforward. Typically, steroids are delivered s.c. or i.p.
Alternatively, currently available MR contrast probes are
commonly injected i.v. or administered orally. Given that a
PR-targeted MR probe is mixture of the two aforementioned
components explicitly testing the route of administration for
effectively targeting PR-expressing tissues is a necessary
foundation of this study.
Complex 1 was the only probe tested that could be
completely dissolved into a saline solution and therefore was
the only appropriate contrast agent to investigate the
importance of delivery route. Although the binding and cellular
association of this complex was significantly lower than the
others under investigation, it was the least toxic. If i.v. delivery
were essential to targeting tissues far from the peritoneal cavity
such as mammary tissue, then this would allow for the use of a
higher concentration of agent when performing in vivo studies
with this probe, and, as mentioned, a higher concentration of
this probe allows it to bind and activate PR comparably to the
others. The mammary tissue, not located in the peritoneal
cavity, showed no preference for delivery route. Intraperitoneal
injections led to the highest concentration of Gd(III) to be
found in the uterus compared with the ovary and mammary
gland. This concentration of Gd(III) was highly retained even
after 24 h, with no adverse effects observed in the animals.
Intravenous administration allowed the probe to access and
accumulate selectively in PR-rich tissues, albeit to a lesser extent
than i.p. administration in tissues located within the peritoneal
cavity. Intravenously delivered compounds must circulate
systemically and likely become bound to serum hormone
binding globulin. The observed increased accumulation in the
uterus (at both 6 and 24 h) and ovary (at 24 h) following i.p.
injection could be due to direct contact with the tissue, since
both tissues are located in the peritoneal cavity, leading to an
effectively higher concentration of 1 in the tissue.
In vivo imaging with complex 1 was not able to distinguish
PR(+) from PR(−) tumors more effectively than previously
tested complex 4. Analysis of Gd(III) concentration by ICP-MS
reveals higher average retention of 1 in the PR(+) tumor
compared with that in the PR(−) tumor, but not significantly.
The increase in field strength (from 7 to 9.4 T) prevents an
exact comparison between complex 4 and current work;
however, at the same concentration and using the same
xenograft model, complex 4 provided significant enhancement
in contrast-to-noise of PR(+) versus PR(−) tumors in vivo.
Mice recovered quickly after injection with 1, and no toxicity in
the animal was observed.
In conclusion, a series of PR-targeted MR contrast agents
with varying linker lengths was developed to impact solubility.
These agents associated with cells and activated PR to varying
extents. Toxicity and lipophilicity was shown to increase with
increasing linker length. Despite the findings that complex 4
was more effective in binding and activating PR, the hydrophilic
properties of complex 1 permit it to be used safely at higher
concentrations and to investigate the route of delivery for
targeting PR-expressing tissues. 1 accumulates in tissues that
express a high concentration of PR, but i.v. delivery, made
possible by changes to water solubility, did not improve
targeting to PR-expressing tissues. MR contrast was enhanced
at 9.4 T, but 1 did not display a marked improvement over the
previously investigated 4. This demonstrates that focusing
Figure 7. In vivo imaging at 9.4 T after injection of complex 1 i.p. (A)
MR image before injection, on the left, and 6 h after injection, on the
right. PR(+) and PR(−) tumors are indicated by arrows. Positive
enhancement is observed in the tumors. (B) Gd(III) concentration in
the tissues harvested as quantified by ICP-MS. Gd(III) concentration
was not significantly different between the tumor types.
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solely on the water solubility of the probe will not easily yield
an optimized contrast agent for the imaging of hormone-
dependent disease in vivo. Further optimization is required to
develop the most effective probe to fulfill this urgent clinical
need for noninvasive imaging of hormone-dependent diseases.
■ EXPERIMENTAL PROCEDURES
General Materials and Methods. Unless otherwise noted,
materials and solvents were purchased from Sigma-Aldrich
Chemical Co. (St. Louis, MO) and used without further
purification. Gd(III)Cl3·6H2O and 1,4,7,10-tetraazacyclodode-
cane (cyclen) were purchased from Strem Chemicals (New-
buryport, MA) and used without further purification. All
reactions were performed under an inert nitrogen atmosphere.
THF, acetonitrile, and dichloromethane were purified using a
Glass Contour Solvent system. Deionized water was obtained
from a Millipore Q-Guard System equipped with a quantum Ex
cartridge (Billerica, MA). Thin-layer chromatography (TLC)
was performed on EMD 60F 254 silica gel plates. Visualization
of the developed chromatogram was performed by CAM stain,
potassium permanganate stain, and platinum stain. Standard
grade 60 Å 230−400 mesh silica gel (Sorbent Technologies)
was used for flash column chromatography. 1H and 13C NMR
spectra were obtained on a Bruker 500 MHz Avance III NMR
Spectrometer with deuterated solvent as noted. Electrospray
ionization mass spectrometry (ESI-MS) spectra were acquired
on a Varian 1200 L single-quadrupole mass spectrometer.
High-resolution mass spectrometry data were acquired on an
Agilent 6210 LC-TOF (ESI, APCI, APPI). Analytical reverse-
phase HPLC-MS was performed on a Varian Prostar 500
system with a Waters 4.6 × 250 mm 5 μM Atlantis C18
column. This system is equipped with a Varian 380 LC ELSD
system, a Varian 363 fluorescence detector, and a Varian 335
UV−vis detector. Preparative runs were performed on a Waters
19 × 250 mm Atlantis C18 column. Mobile phase consisted of
water (solvent A) and HPLC-grade acetonitrile (solvent B) or
0.05% TFA in water (solvent C) and HPLC-grade acetonitrile
(solvent B).
Synthesis. {1,4,7-Tris(carboxymethyl)-10-[10-(6-(2-
( ( 1 0 R , 1 3 S , 1 7 S ) - 1 0 , 1 3 - d i m e t h y l - 3 - o x o -
2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)hexyl]-
1,4,7,10-tetraazacyclododecanato}gadolinium (4, ProGlo).
The synthesis and purification of ProGlo was performed as
previously described.32
{ 1 , 4 , 7 - T r i s ( c a r b o x y m e t h y l ) - 1 0 - [ 1 0 - ( 2 -
( (8S ,9S ,10R ,13S ,14S ,17S ) -10 ,13 -d imethy l -3 -oxo -
2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-17-yl)-2-oxoethyl]-1,4,7,10-
tetraazacyclododecanato}gadolinium (1). The synthesis and
purification of 1 was performed as previously described.32
1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacy-
clododecane (DO3A-tris-tert butyl ester, 9). Cyclen (5 g, 29.0
mmol) and NaHCO3 (5.50 g, 65.5 mmol) were dissolved in
anhydrous acetonitrile (150 mL). tert-Butylbromoacetate (9.60
mL, 65.0 mmol) was added dropwise under nitrogen to the
solution, which was stirred at room temperature for 48 h. After
filtration of the NaHCO3 and removal of the acetonitrile by
rotary evaporation, the remaining crude product was dissolved
in dichloromethane and washed with water. Recrystallization
from toluene yielded an off-white solid (6.05 g, 40%). 1H NMR
(500 MHz, chloroform-d) δ 3.38−2.88 (m, 21H), 1.47 (s,
27H). 13C NMR (125 MHz, chloroform-d) δ 170.76, 169.87,
82.07, 81.93, 58.49, 51.59, 51.17, 49.41, 47.79, 28.47, 28.43.
ESI-MS m/z [M + H]+: 515.1.
{1 ,4 ,7-Tr is (tert-butoxycarbonylmethyl) -1 ,4 ,7 ,10-
tetraazacyclododecanato}gadolinium (Gd(III)-DO3A). A sol-
ution of 9 (0.750 g, 1.46 mmol) in trifluoroacetic acid (2 mL)
was stirred at room temperature for several hours. After
removal of the trifluoroacetic acid, the crude free ligand was
resuspended in water, and the pH was adjusted to 6. A solution
of Gd(III)Cl3 in water was added slowly while maintaining the
pH between 5.5 and 6.5 with 0.5 M NaOH. The solution was
heated at 60 °C and stirred under nitrogen, and the pH was
monitored and readjusted to maintain the pH between 5.5 and
6.5 with additional 0.5 M NaOH. The reaction mixture was
lyophilized and purified by HPLC using a ramp from 0 to 100%
B over 20 min to afford a white solid (0.470 g, 94%). HRMS
(ESI) m/z: found, 502.09519 [M + H]+ (calcd, 502.09314 for
C14H24N4O6Gd(III)).
(10R,13S,17S)-17-(2-(4-Bromobutoxy)acetyl)-10,13-di-
methyl-7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-
cyclopenta[a]phenanthren-3(2H)-one (5). To a mixture of 21-
hydroxyprogesterone (0.500 g, 0.151 mmol) and 40% KOH
(750 μL) was added 1,4-dibromobutane (3.6 mL, 30.3 mmol)
and NBu4OH (150 μL). The reaction mixture was stirred at
room temperature for 16 h, diluted in dichloromethane, and
washed with water three times. The organic layer was dried
over sodium sulfate and concentrated by rotary evaporation.
Flash chromatography in mobile phase 3:1 hexanes/ethyl
acetate yielded the final product as a colorless oil (0.301 g,
43%). 1H NMR (500 MHz, CDCl3) δ 5.61 (s, 1H), 3.93 (dd, J
= 28, 17.1 Hz, 2H), 3.40 (t, J = 6 Hz, 2H), 3.36 (t, J = 6.5 Hz,
2H), 2.50 (t, J = 9 Hz, 1H), 2.31−0.86 (complex, 23H), 1.08 (s,
3H), 0.57 (1, 3H). 13C NMR (125 MHz, CDCl3) δ 208.23,
199.27, 170.94, 123.72, 76.90, 70.36, 58.35, 55.96, 53.40, 44.37,
38.43, 38.39, 35.53, 35.38, 33.79, 33.70, 32.64, 31.76, 29.33,
28.00, 24.39, 22.69, 20.85, 17.23, 13.43. ESI-MS m/z [M + H]+:
465.45
(10R,13S,17S)-17-(2-(4-Bromopentoxy)acetyl)-10,13-di-
methyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-
cyclopenta[a]phenanthren-3(2H)-one (6). A mixture of 21-
hydroxyprogesterone (200 mg, 0.605 mmol), 1,5-dibromopen-
tane (1.65 mL, 12.1 mmol), 40% KOH (300 μL), and
tetrabutylammonium hydroxide (60 μL) was stirred for 16 h at
room temperature. The reaction mixture was diluted in
dichloromethane and washed with water three times. The
organic layer was dried over sodium sulfate and concentrated
by rotary evaporation. The crude residue was purified by flash
chromatography with hexanes/ethyl acetate (2:1) as the mobile
phase to afford 6 as a colorless oil (125 mg, 43%). 1H NMR
(500 MHz, CDCl3) δ 5.67 (s, 1H), 3.96 (q, J = 17.2 Hz, 2H),
3.41 (t, J = 6.4 Hz, 2H), 3.38−3.31 (m, 2H), 2.56 (t, J = 9.1 Hz,
1H), 2.40−2.09 (m, 6H), 1.96 (dd, J = 9.6, 3.8 Hz, 1H), 1.90−
1.74 (m, 5H), 1.72−1.16 (m, 14H), 1.12 (s, 3H), 1.05−0.86
(m, 2H), 0.65−0.58 (m, 3H). 13C NMR (125 MHz, CDCl3) δ
207.55, 198.50, 169.94, 122.92, 75.79, 70.34, 61.56, 57.43,
55.12, 52.51, 43.53, 37.54, 34.61, 32.85, 31.74, 31.47, 30.82,
28.69, 27.74, 23.77, 23.47, 21.81, 19.97, 16.34, 12.55. ESI-MS
m/z [M + H]+: 481.1.
Tri-tert-butyl 2,2′,2″-(10-(4-(2-((10R,13S,17S)-10,13-di-
methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradeca-
hydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)-
butyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
(7). To a solution of 5 (0.301 g, 0.0648 mmol) in anhydrous
acetonitrile was added 9 (0.401 g, 0.0778 mmol), K2CO3
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(0.269 g, 1.95 mmol), and NBu4OH (15 μL). The mixture was
heated at 60 °C for 48 h under N2. Following filtration of the
K2CO3, the solvent was removed by rotary evaporation. The
crude residue was purified by flash chromatography (20:1
dichloromethane/methanol) to afford the final product as a
solid (0.142 g, 25%). 1H NMR (500 MHz, CDCl3) δ 5.56 (s,
1H), 3.90 (m, 2H), 3.30−0.79 (complex, 50H), 1.30 (m, 27H),
1.02 (s, 3H), 0.52 (s, 3H). 13C NMR (125 MHz, CDCl3) δ
207.85, 199.27, 173.31, 172.29, 170.91, 170.38, 169.81, 123.65,
82.62, 82.39, 81.54, 81.36, 76.80, 70.97, 58.70, 58.40, 56.23,
55.82, 53.30, 50.96, 49.90, 48.83, 44.23, 38.34, 35.44, 35.27,
33.71, 32.54, 31.63, 29.43, 27.96, 27.74, 27.59, 27.34, 24.26,
23.91, 22.65, 22.52, 22.23, 20.74, 19.53, 17.14, 13.55, 13.33.
ESI-MS m/z [M + H]+: 899.5, [M + Na]+: 921.5.
Tri-tert-butyl 2,2′,2″-(10-(5-(2-((10R,13S,17S)-10,13-di-
methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradeca-
hydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)-
pentyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
(8). To a solution of 6 (0.368 g, 0.0770 mmol) in anhydrous
acetonitrile were added 9 (0.475 g, 0.0923 mmol), K2CO3
(0.319 g, 2.31 mmol), and NBu4OH (15 μL). The mixture was
heated at 60 °C for 48 h. Following filtration of the K2CO3, the
solvent was removed by rotary evaporation. The crude residue
was purified by flash chromatography (20:1 dichloromethane/
methanol) to afford the final product as a solid (0.388 g, 55%).
1H NMR (500 MHz, CDCl3) δ 5.60 (s, 1H), 3.94 (m, 2H),
3.38−0.85 (complex, 52H), 1.34 (m, 27H), 1.07 (s, 3H), 0.56
(s, 3H). 13C NMR (125 MHz, CDCl3) δ 208.11, 199.32,
172.42, 170.92, 169.84, 123.73, 82.60, 82.31, 81.59, 71.31,
58.46, 55.92, 55.57, 53.52, 53.40, 44.31, 38.42, 35.54, 35.37,
33.80, 32.64, 31.72, 29.41, 28.05, 28.00, 27.84, 27.68, 26.07,
24.36, 23.92, 22.73, 20.83, 17.23, 13.41. ESI-MS m/z [M + H]+:
914.5, [M + Na]+: 936.40
{2,2′,2″-(10-(4-(2-((10R,13S,17S)-10,13-Dimethyl-3-oxo-
2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)butyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate}-
gadolinium (2). A solution of 7 (1 equiv) in formic acid was
stirred at room temperature for 4 h. The reaction mixture was
concentrated in vacuo and resuspended in water. Gd(III)Cl3·
6H2O (1.1 equiv) was added, and the solution was heated at 60
°C and stirred under nitrogen. The pH was monitored and
maintained between 5.5 and 6.5 (using 0.5 M NaOH). The
reaction mixture was lyophilized and purified by HPLC using a
ramp from 30 to 100% B over 20 min. Analytical HPLC-MS
was used to confirm the purity and identity of the collected
fractions. Pure fractions were freeze-dried and stored in a
desiccator. ESI-MS m/z [M + H]+: 886.3.
2,2′,2″-(10-(5-(2-((10R,13S,17S)-10,13-Dimethyl-3-oxo-
2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)pentyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (3).
A solution of 8 (1 equiv) in formic acid was stirred at room
temperature for 3−4 h. The reaction mixture was concentrated
in vacuo and resuspended in water. Gd(III)Cl3·6H2O (1.1
equiv) was added, and the solution was heated at 60 °C and
stirred under nitrogen. The pH was monitored and maintained
between 5.5 and 6.5 (using 0.5 M NaOH). The reaction
mixture was lyophilized and purified by HPLC using a ramp
from 30 to 100% B over 20 min. Analytical HPLC-MS was used
to confirm the purity and identity of the collected fractions.
Pure fractions were freeze-dried and stored in a desiccator. ESI-
MS m/z [M + H]+: 899.5.
Relaxivity. Solutions of 1−4 were prepared in 400 μL of
Millipore water containing 1% DMSO for T1 and T2 acquisition
to a concentration of 0.500 mM. DMSO was required for
solubility of 2−4. DMSO can affect relaxivity in that protons
are shifted downfield, but, as the concentration of DMSO used
for these studies is so low, little effect from the solvent mixture
is observed. Serial dilutions were performed to yield the
experimental concentrations of 0.500, 0.250, 0.125, 0.063, and
0.031 mM. T1 and T2 relaxation times were measured on a
Bruker mq60 NMR analyzer equipped with Minispec V2.51
Rev.00/NT software (Billerica, MA) operating at 1.41 T (60
MHz) and 37 °C. T1 relaxation times were measured using an
inversion recovery pulse sequence (t1_ir_mb) using the
following parameters: 4 scans per point, 10 data points for
fitting, monoexponential curve fitting, phase cycling, 10 ms first
pulse separation, and a recycle delay and final pulse separation
≥ 5T1. Measurements were performed in triplicate. The
Gd(III) concentration of each solution was determined using
ICP-MS on a computer-controlled (Plasmalab software)
Thermo X series II ICP-MS (Thermo Fisher Scientific,
Waltham, MA, USA) operating in standard mode equipped
with an ESI SC-2 autosampler (Omaha, NE). The inverse of
the relaxation time (1/T1, s
−1) (taken as the average of the
three replicates) was plotted against Gd(III) concentration
(mM) and fitted to a straight line with R2 > 0.99. The slope of
the fitted line was recorded as the relaxivity, r1.
Octanol−Water Partition Coefficients. Each complex
(0.5 mg) was dissolved in 1 mL of a 1:1 mixture of water/1-
octanol. After shaking the sample tube vigorously for 30 s, the
tube was placed on a rotator for gentle mixing for 4 h. The tube
was removed from the rotator, and complete separation of the
aqueous and organic phases was allowed over 10 h. Fifty
microliters was removed from each layer and subjected to ICP-
MS to determine the Gd(III) concentration in each layer. The
partition coefficient was calculated from the following equation
= C
C
logP log o
w
where logP is the logarithm of the partition coefficient, Co is the
concentration of Gd(III) in the 1-octanol layer, and Cw is the
concentration of Gd(III) in the water layer.
ICP-MS Sample Preparation and Instrument Parame-
ters. For logP measurements, ACS reagent grade nitric acid
(70%) was added to solutions of the agent in water or 1-octanol
(for a 1.0:1.0 v/v sample/nitric acid) in 15 mL conical tubes
and placed at 65 °C for 4 h to allow for complete sample
digestion. For samples in 1-octanol, caps were removed from
tubes and replaced to vent tubes every 30 min due to the
buildup of pressure. Filtered, deionized H2O (18.2 MΩ·cm)
and multielement internal standard containing Bi, Ho, In, Li,
Sc, Tb, and Y (Inorganic Ventures, Christiansburg, VA) were
added to produce a final solution of 3.0% nitric acid (v/v) and
5.0 ng/mL internal standard. Instrument calibration was
accomplished by preparing individual-element Gd(III)(III)
standards (Inorganic Ventures, Christiansburg, VA, USA)
using concentrations of 0.7813, 1.563, 3.125, 6.250, 12.50,
25.00, 50.00, 100.0, and 200.0 ng/mL containing 3.0% nitric
acid (v/v) and 5.0 ng/mL of the multielement internal
standard.
General Cell Culture and Animal Studies. Dulbecco’s
modified phosphate buffered saline (DPBS), media, sera, and
dissociation reagents were purchased from Invitrogen (Carls-
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bad, CA). Cell culture consumables (flasks, plates, etc.) were
purchased from VWR (Radnor, PA). Charcoal dextran stripped
FBS was purchased from Atlanta Biologicals (Lawrenceville,
GA). MDA-MB-231 cells were cultured using phenol red free
α-MEM (modified to contain 20 ng/mL insulin) supplemented
with 10% FBS (characterized) or with 10% charcoal dextran
stripped FBS. T47D cells were cultured using phenol red free
RPMI 1640 (modified to contain 1.0 mM sodium pyruvate, 1.0
mM HEPES, and 4.5 g/L glucose) supplemented with 10%
FBS or 10% charcoal dextran stripped FBS. Prior to all
experiments, cells were plated in the appropriate media
containing FBS. After plating, this media was replaced with
media containing charcoal dextran stripped FBS and incubated
at 37 °C in a 5.0% CO2 incubator for 24 h at which point the
media was replaced with fresh charcoal dextran stripped FBS
containing media, and the cells were incubated an additional 24
h prior to beginning the experiment. MDA-MB-231 and T47D
cells were harvested by incubation with 0.25% TrypLE for 10
min at 37 °C in a 5.0% CO2 incubator. All incubations were
carried out at 37 °C in a 5.0% CO2 incubator unless otherwise
specified.
Female CD-1 mice, acquired from Harlan (Indianapolis, IN),
and female Balb/C athymic nude mice, acquired from Charles
River (Wilmington, MA), were housed under pathogen-free
conditions. All animal studies were conducted at University of
Illinois at Chicago in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and
established institutional animal use and care protocols.
Cell Counting and Percent Cell Viability Determi-
nation Using Guava EasyCyte Mini Personal Cell
Analyzer (PCA) System. After cell harvesting, an aliquot
(15 or 30 μL) of the cell suspensions was mixed with Guava
ViaCount reagent (final sample volume of 150 μL) and
incubated at room temperature for 5 min. After incubation,
samples were vortexed for 10 s. Cells were counted, and
percent cell viability was determined via manual analysis using a
Guava EasyCyte Mini Personal Cell Analyzer (PCA) and
ViaCount software module. For each sample, 1000 events were
acquired with dilution factors that were determined on the basis
of the optimum machine performance (∼25−70 cells/μL).
Instrument reproducibility was assessed daily using Guava-
Check Beads and following the manufacturer’s suggested
protocol using the Daily Check software module.
Cellular Uptake Studies. Cells (either T47D or MDA-
MB-231) were plated at 12 000 cells per well in a 48-well plate.
Contrast agents were dissolved in DMSO to obtain a stock
solution of 100 mM. An incubation solution of 0.125 mM
contrast agent was made by diluting the stock solution in the
appropriate media (containing stripped FBS) for each cell line
(T47D and MDA-MB-231). Cells were incubated with 150 μL
of the 0.125 mM solution for 1, 4, and 8 h. After incubation, the
media was removed, and the cells were rinsed twice with 0.500
mL of DPBS and harvested by incubation with 50 μL of 0.25%
TrypLE for 10 min at 37 °C in a 5.0% CO2 incubator. Fifty
microliters of media was added to each well, a 30 μL aliquot
was removed for cell counting, and a 60 μL aliquot was
analyzed for Gd(III) content by ICP-MS. Each condition was
done in triplicate.
Cytotoxicity: MTS Assay. The CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay (Promega, Madison, WI)
was used to measure cell viability. Cells, either T47D or MDA-
MB-231, were plated at 500−1000 cells/well in 96−well plates
and maintained in media containing charcoal stripped serum
for 48 h before the experiment. 4-Hydroxytamoxifen, 1, 2, 3, 4,
and Gd(III)-DO3A were dissolved in DMSO to make a stock
solution of 100 mM. Solutions were diluted to the experimental
concentrations (10.0, 5.00, 2.5, 1.25, 0.625, 0.313, 0.156 mM)
in media. After 48 h of incubation with 50 μL of solution, the
assay was run according to the manufacturer’s protocol.
Absorbance at 490 nm was measured using a Synergy4
microplate reader (BioTek, Winooski, VT). Percent toxicity
was calculated on the basis of the absorbance.
Luciferase Assay for PR Activation. T47D cells were
grown in phenol red-free medium, and the cells were
trypsinized and plated in 24-well plate (50 000 cells/well).
Incubation of cells with pPRE-luciferase plasmid (100 ng/well,
construct provided by Dr. Ken Korach, NIEHS, NIH), RSV-β-
galactosidase (100 ng/well, provided by Dr. William T. Beck,
University of Illinois at Chicago), and Lipofectamine 2000 (1
μL per well, Invitrogen, Carlsbad, CA) in Opti-MEM was
performed overnight at 37 °C inside a humidified incubator.
The cells were treated with complexes 1−4 or controls for an
additional 24 h.
To measure luciferase production, cells were lysed in 100 μL
of GME buffer [25 mM glycylglycine (pH 7.8), 15 mM
MgSO4, 4 mM EGTA, 1 mM dithiothreitol, and 1% Triton X-
100], and lysates were added to assay buffer (GME buffer, 16.5
mM KPO4, 2.2 mM ATP, and 1.1 mM dithiothreitol).
Luciferase substrate was injected followed by a 30 s read by a
FLUOstar OPTIMA (BMG Lab Tech, Offenburg, Germany).
LacZ activity (50 μL lysate) was measured from cleavage of
ONPG. The sample results were normalized to β-galactosidase
to account for transfection efficiency by dividing the sum of the
luciferase activity by the sum of the β-galactosidase activity.
qPCR. T47D cells were plated at 300 000 cells/well in 6−
well plates in phenol red-free RPMI1640 media supplemented
with 4.5 g/L glucose and 10% charcoal dextran stripped FBS.
Twenty four hours later, cells were washed once with 1× PBS
and incubated with contrast agents in DMSO or DMSO only in
fresh phenol red-free RPMI1640 media supplemented with 4.5
g/L glucose and 10% charcoal dextran stripped FBS for 24 h.
After treatment, cells were harvested in 0.5 mL of Trizol, and
RNA was extracted using the manufacturer’s protocol. RNA
was treated with DNaseI (New England Biolabs, Ipswich, MA)
for 10 min at 37 °C followed by inactivation at 75 °C for 10
min. RNA samples (1 μg) were primed with random primers
(Promega, Madison, WI) and then reverse transcribed using
Revertaid Reverse Transcriptase (Fermentas, Glen Burnie,
MD) according to the manufacture’s protocol. For PCR
amplification, the cDNA was diluted 1:10, and 1 μL was used in
an 11 μL reaction using FastStart Universal SYBR Green
Master Mix (ROX) (Roche) in a VIIA7 Real Time PCR System
(Life Technologies) under the following conditions: hold at 94
°C for 10 min, followed by 40 cycles of 95 °C for 10 s and 60
°C for 30 s. The primers for ZBTB16 and GAPDH were used
at 0.5 μM and were the same as described.35 Induction of
ZBTB16 was normalized to GAPDH, and fold change was
calculated using the ΔΔCt method.
Biodistribution. Animals were injected with 0.15 mmol/kg
body weight of 1. After an incubation of 6 or 24 h, organs were
harvested, and quantification of Gd(III) was performed using
ICP-MS of acid-digested samples. For organ digestion, Teflon
tubes were boiled in a mixture of ∼1−5% Alconox (w/v) and
3.0% (v/v) ACS reagent grade nitric acid (70%) to ensure
complete removal of lipid and residual Gd(III). The tubes were
washed with filtered, deionized H2O (18.2 MΩ·cm) and air-
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dried. Organs were weighed in clean Teflon tubes followed by
the addition of 1 mL of ACS reagent grade nitric acid (70%)
per gram of tissue. Samples were digested in a Milestone
EthosEZ microwave digestion system (Shelton, CT, USA) with
a 120 °C temperature ramp for 30 min (600 W) and a 120 °C
hold for 30 min (400 W), followed by a 45 min exhaust cycle.
The resultant liquefied organ samples were weighed, with a
portion of each sample being placed in a clean preweighed 15
mL conical tube followed by addition of multielement internal
standard and filtered, deionized H2O (18.2 MΩ·cm) to
produce a final solution of 3.0% nitric acid (w/w) and 5 ng/
mL multielement internal standard containing Bi, Ho, In, Li, Sc,
Tb, and Y (Inorganic Ventures, Christiansburg, VA) and
filtered, deionized H2O (18.2 MΩ·cm) to a final volume of 5
mL. Instrument calibration was performed by preparing
individual-element Gd(III)(III) standard (Inorganic Ventures,
Christiansburg, VA) using concentrations of 1.000, 5.000,
10.00, 20.00, 50.00, 100.0, and 200.0 ng/mL containing 3.0%
nitric acid (v/v) and 5.0 ng/mL of the multielement internal
standard.
Tumor Xenograft Model. A 17β-estradiol pellet (In-
novative Research of America, Sarasota, FL, 70 day release, 0.72
mg/pellet) was implanted in the nape of the neck of athymic
nude mice due to their intrinsic low circulating estradiol levels.
This pellet ensures the growth of the estrogen-dependent
T47D cells. Two days later, T47D and MDA-MB-231 ((1−2)
× 106) cells were suspended in Matrigel (1:1 ratio by volume)
and injected into the rear flanks (MDA-MB-231 cells on the
right and T47D on the left). Mice were monitored for tumor
growth every other day after inoculation. Mice were imaged
when tumors were palpable.
In Vivo MR Imaging. Xenografted nude mice (n = 2) were
injected i.p. with complex 1 at a concentration of 0.15 mmol/kg
mouse weight dissolved in buffered saline solution. During
imaging, mice were held under anesthesia (1−3% inhaled
isoflurane). Mice were allowed to regain consciousness and
recover in between imaging time points. Tubing containing
heated water was placed under the animals to maintain a
constant body temperature. All imaging experiments were
performed on a 30 cm bore BioSpec 9.4 T MR imager fitted
with 12 cm gradient inserts (Bruker BioSpin, Billerica, MA)
using a 40 mm quadrature volume coil.
Standard T1-weighted rapid acquisition rapid echo (RARE)
scans were used for imaging the xenografts. The parameters
were as follows: TR = 1500 ms, TE = 8.5 ms, flip angle =
180.0°, FOV = 3 cm, matrix size = 256 × 256, slice thickness =
0.75 mm, and interslice distance = 0.75 mm. Images were
analyzed using the ImageJ software package. Contrast-to-noise
ratios (CNR) were calculated using the equation CNR =
(SItissue − SImuscle)/σnoise, where SItissue is the signal intensity in
the tissue of interest or tumor mass, SImuscle is the signal
intensity in the muscle, and σnoise is the standard deviation of
the noise. CNRs were averaged over two to three axial slices in
which the tumors were clearly visible.
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